Why the study?
Does oral Ro-30837 prolong bleeding time and increase blood loss in humans?
Does oral Ro-30837 prolong bleeding time and increase blood loss in humans?
Oral administration of Ro-30837 prolongs bleeding time and increases blood loss, likely by decreasing platelet adhesiveness.
May increase bleeding risk with use; leaves open therapeutic potential pending controlled trials.
Summary Ro-30837 given by mouth to seven people produced a variable but definite prolongation of the bleeding time and greater blood loss. This effect was probably due to a decrease in platelet adhesiveness.
No takes yet. Share an insight, caveat, or question.
J.R. O’Brien (1963) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: